Atherosclerosis
Volume 183, Issue 2 , Pages 222-229 , December 2005

Apolipoprotein A-I and the molecular variant apoA-IMilano: Evaluation of the antiatherogenic effects in knock-in mouse model

  • Cinzia Parolini

      Affiliations

    • Department of Pharmacological Sciences, University of Milan, 20133 Milan, Italy
    • Corresponding Author InformationCorresponding author. Tel.: +39 02 50318328; fax: +39 02 50318284.
    • ,
  • Giulia Chiesa

      Affiliations

    • Department of Pharmacological Sciences, University of Milan, 20133 Milan, Italy
    • ,
  • Elaine Gong

      Affiliations

    • Genome Sciences Department, Lawrence Berkeley National Laboratory, Berkeley, CA 94720, USA
    • ,
  • Silvia Caligari

      Affiliations

    • Department of Pharmacological Sciences, University of Milan, 20133 Milan, Italy
    • ,
  • Miriam M. Cortese

      Affiliations

    • Department of Pharmacological Sciences, University of Milan, 20133 Milan, Italy
    • ,
  • Teiichiro Koga

      Affiliations

    • Genome Sciences Department, Lawrence Berkeley National Laboratory, Berkeley, CA 94720, USA
    • ,
  • Trudy M. Forte

      Affiliations

    • Genome Sciences Department, Lawrence Berkeley National Laboratory, Berkeley, CA 94720, USA
    • ,
  • Edward M. Rubin

      Affiliations

    • Genome Sciences Department, Lawrence Berkeley National Laboratory, Berkeley, CA 94720, USA

Received 16 September 2004 ,Revised 1 March 2005 ,Accepted 14 March 2005.

References 

  1. Franceschini G, Sirtori CR, Capurso A, Weisgraber KH, Mahley RW. A-IMilano apoprotein. Decreased high density lipoprotein cholesterol levels with significant lipoprotein modifications and without clinical atherosclerosis in an Italian family. J Clin Invest. 1980;66:892–900
  2. Franceschini G, Sirtori CR, Bosisio E, et al. Relationship of the phenotypic expression of the A-IMilano apoprotein with plasma lipid and lipoprotein patterns. Atherosclerosis. 1985;58:159–174
  3. Gualandri V, Franceschini G, Sirtori CR, et al. A-IMilano apoprotein identification of the complete kindred and evidence of a dominant genetic transmission. Am J Hum Genet. 1985;37:1083–1097
  4. Sirtori CR, Calabresi L, Franceschini G, et al. Cardiovascular status of carriers of the apolipoprotein A-I(Milano) mutant: the Limone sul Garda study. Circulation. 2001;103:1949–1954
  5. Bielicki JK, Oda MN. Apolipoprotein A-I(Milano) and apolipoprotein A-I(Paris) exhibit an antioxidant activity distinct from that of wild-type apolipoprotein A-I. Biochemistry. 2002;41:2089–2096
  6. Franceschini G, Calabresi L, Chiesa G, et al. Increased cholesterol efflux potential of sera from ApoA-I(Milano) carriers and transgenic mice. Arterioscler Thromb Vasc Biol. 1999;19:1257–1262
  7. Shah PK, Nilsson J, Kaul S, et al. Effects of recombinant apolipoprotein A-I(Milano) on aortic atherosclerosis in apolipoprotein E-deficient mice. Circulation. 1998;97:780–785
  8. Ameli S, Hultgardh-Nilsson A, Cercek B, et al. Recombinant apolipoprotein A-IMilano reduces intimal thickening after balloon injury in hypercholesterolemic rabbits. Circulation. 1994;90:1935–1941
  9. Soma MR, Donetti E, Parolini C, Sirtori CR, Fumagalli R, Franceschini G. Recombinant apolipoprotein A-IMilano dimer inhibits carotid intimal thickening induced by perivascular manipulation in rabbits. Circ Res. 1995;76:405–411
  10. Chiesa G, Monteggia E, Marchesi M, et al. Recombinant apolipoprotein A-I(Milano) infusion into rabbit carotid artery rapidly removes lipid from fatty streaks. Circ Res. 2002;90:974–980
  11. Nissen SE, Tsunoda T, Tuzcu EM, et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. J Am Med Assoc. 2003;290:2292–2300
  12. Parolini C, Chiesa G, Zhu Y, et al. Targeted replacement of mouse apolipoprotein A-I with human ApoA-I or the mutant ApoA-IMilano. Evidence of APOA-IM impaired hepatic secretion. J Biol Chem. 2003;278:4740–4746
  13. Callow MJ, Stoltzfus LJ, Lawn RM, Rubin EM. Expression of human apolipoprotein B and assembly of lipoprotein (a) in transgenic mice. Proc Natl Acad Sci USA. 1994;91:2130–2134
  14. Schultz JR, Gong EL, McCall MR, Nichols AV, Clift SM, Rubin EM. Expression of human apolipoprotein A-II and its effect on high density lipoproteins in transgenic mice. J Biol Chem. 1992;267:21630–21636
  15. Guide for the Care and Use of Laboratory Animals published by the US National Institute of Health-NIH Publication No. 85–23, revised 1996.
  16. Nishina PM, Verstuyft J, Paigen B. Synthetic low and high fat diets for the study of atherosclerosis in the mouse. J Lipid Res. 1990;31:859–869
  17. Allain CC, Poon LS, Chan CS, Richmond W, Fu PC. Enzymatic determination of total serum cholesterol. Clin Chem. 1974;20:470–475
  18. Chiesa G, Stoltzfus LJ, Michelagnoli S, et al. Elevated triglycerides and low HDL cholesterol in transgenic mice expressing human apolipoprotein A-I(Milano). Atherosclerosis. 1998;136:139–146
  19. Callow MJ, Verstuyft J, Tangirala R, Palinski W, Rubin EM. Atherogenesis in transgenic mice with human apolipoprotein B and lipoprotein (a). J Clin Invest. 1995;96:1639–1646
  20. Purcell-Huynh DA, Farese RV, Johnson DF, et al. Transgenic mice expressing high levels of human apolipoprotein B develop severe atherosclerotic lesions in response to a high-fat diet. J Clin Invest. 1995;95:2246–2257
  21. Nishina PM, Verstuyft J, Paigen B. Synthetic low and high fat diets for the study of atherosclerosis in the mouse. J Lipid Res. 1990;31:859–869
  22. Vergnes L, Phan J, Strauss M, Tafuri S, Reue K. Cholesterol and cholate components of an atherogenic diet induce distinct stages of hepatic inflammatory gene expression. J Biol Chem. 2003;278:42774–42784
  23. Voyiaziakis E, Goldberg IJ, Plump AS, Rubin EM, Breslow JL, Huang LS. ApoA-I deficiency causes both hypertriglyceridemia and increased atherosclerosis in human apoB transgenic mice. J Lipid Res. 1998;39:313–321
  24. Li-Hawkins J, Gafvels M, Olin M, et al. Cholic acid mediates negative feedback regulation of bile acid synthesis in mice. J Clin Invest. 2002;110:1191–1200
  25. Parolini C, Colombo N, Milia M, et al. Mechanism of hypertriglyceridemia in human apolipoproteinA-IMilano transgenic mice. 1997 (Abstract).
  26. Rubin EM, Krauss RM, Spangler EA, Verstuyft JG, Clift SM. Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI. Nature. 1991;353:265–267
  27. Plump AS, Scott CJ, Breslow JL. Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse. Proc Natl Acad Sci USA. 1994;91:9607–9611
  28. Schultz JR, Verstuyft JG, Gong EL, Nichols AV, Rubin EM. Protein composition determines the anti-atherogenic properties of HDL in transgenic mice. Nature. 1993;365:762–764
  29. Berard AM, Foger B, Remaley A, et al. High plasma HDL concentrations associated with enhanced atherosclerosis in transgenic mice overexpressing lecithin-cholesteryl acyltransferase. Nat Med. 1997;3:744–749

PII: S0021-9150(05)00209-1

doi: 10.1016/j.atherosclerosis.2005.03.008

Atherosclerosis
Volume 183, Issue 2 , Pages 222-229 , December 2005

Article Tools

* Image Usage & Resolution